OmniAb Inc. (OABI)
$3.78 -$0.22 (-5.63%) 10:12 AM 12/13/24
NASDAQ | $USD | BiotechnologyStock Data
-
Market Cap
$486.47M -
Day's Range
$3.75 - $4.00 -
Volume
444,903 -
52 Week Low / High
$3.56 - $6.72 -
PE Ratio
- -
PEG Ratio
- -
Dividend Frequency
-
- 6
- Strong Buy
- 2
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong Sell
- $10.00
- Target Price
Company News
-
OmniAb Inc (OABI) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ... — Oct 9th, 2024
Total Revenue: $7.6 million for Q2 2024, compared to $6.9 million in the prior year quarter. Service Revenue: Included an accelerated $1.3 million due to the discontinuation of the GSK small molecule ion channel program. R&D Expense: Relatively unchanged versus the prior year. G&A Expense:...
-
OmniAb Inc (OABI) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ... — Oct 9th, 2024
Total Revenue: $7.6 million for Q2 2024, compared to $6.9 million in the prior year quarter. Service Revenue: Included an accelerated $1.3 million due to the discontinuation of the GSK small molecule ion channel program. R&D Expense: Relatively unchanged versus the prior year. G&A Expense:...
-
OmniAb Inc (OABI) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ... — Oct 9th, 2024
Total Revenue: $7.6 million for Q2 2024, compared to $6.9 million in the prior year quarter. Service Revenue: Included an accelerated $1.3 million due to the discontinuation of the GSK small molecule ion channel program. R&D Expense: Relatively unchanged versus the prior year. G&A Expense:...
-
Mighty Minis: 7 Small-Cap Stocks That Punch Above Their Weight — Dec 15th, 2023
While your typical financial advisor will likely direct you to focus on established blue chips to boost your holdings, few other compelling options exist other than powerful small-cap stocks. To be 100% clear, entities that offer significant upside reward potential usually carry significan...
-
OmniAb Inc (OABI) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ... — Oct 9th, 2024
Total Revenue: $7.6 million for Q2 2024, compared to $6.9 million in the prior year quarter. Service Revenue: Included an accelerated $1.3 million due to the discontinuation of the GSK small molecule ion channel program. R&D Expense: Relatively unchanged versus the prior year. G&A Expense:...
-
OmniAb Inc (OABI) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ... — Oct 9th, 2024
Total Revenue: $7.6 million for Q2 2024, compared to $6.9 million in the prior year quarter. Service Revenue: Included an accelerated $1.3 million due to the discontinuation of the GSK small molecule ion channel program. R&D Expense: Relatively unchanged versus the prior year. G&A Expense:...
-
OmniAb Inc (OABI) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ... — Oct 9th, 2024
Total Revenue: $7.6 million for Q2 2024, compared to $6.9 million in the prior year quarter. Service Revenue: Included an accelerated $1.3 million due to the discontinuation of the GSK small molecule ion channel program. R&D Expense: Relatively unchanged versus the prior year. G&A Expense:...
-
OmniAb Inc (OABI) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ... — Oct 9th, 2024
Total Revenue: $7.6 million for Q2 2024, compared to $6.9 million in the prior year quarter. Service Revenue: Included an accelerated $1.3 million due to the discontinuation of the GSK small molecule ion channel program. R&D Expense: Relatively unchanged versus the prior year. G&A Expense:...
-
OmniAb Inc (OABI) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Partnerships ... — Oct 9th, 2024
Total Revenue: $7.6 million for Q2 2024, compared to $6.9 million in the prior year quarter. Service Revenue: Included an accelerated $1.3 million due to the discontinuation of the GSK small molecule ion channel program. R&D Expense: Relatively unchanged versus the prior year. G&A Expense:...
Similar Stocks
Portfolio
Comprised of 1 portfolios